NKGen Biotech(US:NKGN) investorplace.comยท2024-05-20 15:41Company Update - NKGen Biotech has received approval from its Safety Review Committee to commence its Phase 2 clinical study of SNK01, a drug aimed at treating moderate Alzheimer's disease [1][2] - The Phase 1 clinical trial results were positive, showing improved or maintained cognitive abilities after four doses, with no adverse effects reported [2] Clinical Trial Details - The Phase 2 trial will involve a larger patient group, with 20 patients receiving 20 doses of SNK01 and 10 patients receiving 10 placebo doses [2] - The CEO of NKGen Biotech expressed optimism about the clinical progress and the potential for significant clinical and biomarker data from the upcoming trial [3] Stock Performance - Following the announcement, NKGN stock experienced significant trading activity, with over 26 million shares traded, surpassing its average daily volume of 3.7 million shares [3] - As of Monday morning, NKGN stock price increased by 54% [4]